Abstract: A ferroelectric chiral smectic liquid crystal composition, comprising at least one compound represented by the following formula (I): ##STR1## wherein R.sub.1 denotes a linear or branched alkyl group having 1-18 carbon atoms capable of having a substituent, R.sub.2 denotes a linear or branched alkyl group having 1-14 carbon atoms capable of having a substituent; X.sub.1 and X.sub.2 respectively denote a single bond, --O--, ##STR2## m is 0-7; and n is 0 or 1; and at least one compound represented by the following formula (II): ##STR3## wherein R.sub.3 denotes a linear or branched alkyl group having 1-18 carbon atoms capable of having a substituent; R.sub.4 denotes a linear alkyl group having 1-10 carbon atoms; X.sub.3 denotes a single bond, --O--, ##STR4## Y denotes ##STR5## --CH.sub.2 O-- or --OCH.sub.

Abstract: Analogs of cytochalasin B are used as radiopharmaceuticals to provide an image for the nuclear imaging of glucose transport across cell membranes. Like cytochalasin B, the analogs bind specifically to glucose transport protein, and in doing so, serve as markers indicating the amount of glucose transport protein present on the surfaces of cells. The analogs differ from cytochalasin B by the inclusion of a radionuclide in the region of the terminal phenyl group on cytochalasin B, where the radionuclide does not interfere with the binding specificity of the analog. Disclosed herein are such analogs as well as analogs with which readily accept radionuclides at the desired location on the structure, either by conjugation or substitution.

Abstract: .beta.-Al.sub.2 TiO.sub.5 protective coatings have been developed for both dense and porous ceramics such as SiC and Si.sub.3 N.sub.4 using a chemical solution processing method involving the hydrolysis and condensation of aluminum tri-sec butoxide and titanium butoxide. The solution viscosities, pH values, H.sub.2 O/alkoxide molar ratios, and dip coating withdrawal rates required for crack-free .beta.-Al.sub.2 TiO.sub.5 are 1.0 to 6.2 cP, pH 1-4.5, molar ratio 1.5-10, and withdrawal rate of 2.2-8.0 cm/min, respectively. Conversion of the amorphous coating to crystalline .beta.-Al.sub.2 TiO.sub.5 is achieved by a succession of calcination below 450.degree. C. and a final heat-treatment at 1300.degree. C. for ten hours with controlled heating and cooling rates.

Abstract: A method of microencapsulating an agent to form a microencapsulated product, having the steps of dispersing an effective amount of the agent in a solvent containing a dissolved wall forming material to form a dispersion, combining the dispersion with an effective amount of a continuous process medium to form an emulsion that contains the process medium and microdroplets having the agent, the solvent and the wall forming material and adding rapidly the emulsion to an effective amount of an extraction medium to extract the solvent from the microdroplets to form the microencapsulated product.

Abstract: A stable aqueous sol of amorphous alumina containing Al.sub.2 O.sub.3 up to 15% by weight and 0.1 to 0.5 gram equivalent of an anion of acid to 1 mol of aluminum in the sol, in which the colloidal particles of amorphous alumina have a controlled thickness in a range of 20 to 100 millimicrons and a uniform length in a range of 200 to 500 millimicrons is produced by a process comprising feeding an aqueous solution of an acid into an aqueous slurry containing 1 to 7% by weight of metallic aluminum, 10 to 200 ppm by weight as Si0.sub.2 of a water-soluble silicate and 0 to 20 ppm by weight of a water-soluble sulfate as S0.sub.4 to the water in the slurry while maintaining the slurry at a temperature of 80.degree. C. to boiling point under normal pressure, said acid being in an amount of 0.1 to 0.5 gram equivalent to 1 mol of the metallic aluminum in said slurry, at a rate of 0.001 to 0.

Abstract: A method of preparing chlorine dioxide in a non-aqueous liquid is disclosed. An aqueous solution of chlorine dioxide is mixed and agitated with a non-aqueous liquid. The chlorine dioxide is extracted into the non-aqueous liquid. In a preferred embodiment, an aqueous chlorite solution is added to a quantity of non-aqueous liquid. Acid is added to the aqueous phase to generate chlorine dioxide. The phases are vigorously agitated to extract the chlorine dioxide into the non-aqueous phase. High concentrations of very pure chlorine dioxide are obtainable. In another preferred embodiment, chlorine is prepared in a non-aqueous liquid and is mixed and agitated with an aqueous chlorite solution. Separation of the aqueous and non-aqueous phases provides pure solutions of chlorine dioxide in the non-aqueous liquid. Very pure aqueous solutions of chlorine dioxide are prepared by mixing and agitating non-aqueous solutions of chlorine dioxide with water.

Abstract: The invention relates to radiolabeled imaging of a mammalian body. The invention in particular provides for reagents labeled with technetium-99m for such imaging. The invention specifically provides somatostatin, somatostatin derivatives, somatostatin analogues or peptides that bind to the somatostatin receptor and contain at least 2 cysteine residues that form a disulfide or wherein the disulfide is reduced to the sulfhydryl form that are labeled with technetium-99m and that can be targeted to specific sites within a mammalian body for imaging.

Abstract: The invention relates to an aqueous fire retardant solution, a method of making said solution, and a method of using said solution as a coating for cellulosic materials and cellulosic containing materials. The fire retarding solution consists essentially of: ammonium sulfate 3-10% by weight, boric acid 1-5% by weight, borax 0.3-1% by weight, hydrogen peroxide 1-5% by weight, and optionally a surfactant and/or an alkyl phthalate ester.

Abstract: A ferroelectric chiral smectic liquid crystal composition, comprising at least one optically active compound represented by the following formula (I): ##STR1## wherein R.sub.1 and R.sub.2 respectively denote a linear or branched alkyl group having 1-18 carbon atoms capable of having a substituent, at least one of R.sub.1 and R.sub.2 being optically active; X.sub.1 denotes --O--, ##STR2## and X.sub.2 denotes a single bond, --O--, ##STR3## and at least one compound represented by the following formula (II): ##STR4## wherein R.sub.3 and R.sub.4 respectively denote a linear or branched optically inactive alkyl group having 1-18 carbon atoms capable of having an alkoxy group of 1-12 carbon atoms; X.sub.3 and X.sub.4 respectively denote a single bond, --O--, ##STR5## and m and n are respectively 0, 1 or 2 with proviso that both of m and n are not 0.

Abstract: Characteristics of a ferroelectric liquid crystal show that ionic impurities deteriorate its display quality to a great extent. The present invention provides a ferroelectric liquid crystal display device of good display quality without the deterioration of display characteristics, as a result of trapping the ionic impurities effectively by adding an organic material which traps ions and which lowers conductivity of a liquid crystal layer thereto.

Abstract: The present invention relates to methods for detecting the multidrug resistance phenotype in vivo and in vitro. The invention particularly relates to methods of diagnosing the multidrug resistance phenotype by imaging, particularly scintigraphic imaging, in solid tumors in vivo or in tumors and biopsies in vitro. The methods of the present invention allow the diagnosis of multidrug-resistant tumor and other multidrug-resistant phenotypes without invasive surgical methods. The present invention is also directed to methods of treating multidrug resistant tumors with novel agents that bind to P-glycoprotein. The novel compounds of the present invention are co-administered with a chemotherapeutic agent in order to enhance accumulation of the drug.

Abstract: Provided is a nonflammable solvent composition comprising 40% by volume or more of a non-flammable perfluoro organic compound.

Abstract: A titanium oxide sol comprising a disperse medium and generally rectangular, non-spherical particles of titanium oxide dispersed in the disperse medium, with narrow scatteres in particle size and configuration. The sol is excellent in dispersibility, long-term stability and light-resistance and, is stable in a wide pH range without causing agglomeration. Moreover, it is excellent in absorbance of ultraviolet ray and in transmittance of visible light. The sol may be prepared by a process wherein hydrogen peroxide is added to a gel or sol of hydrated titanium oxide to dissolve the hydrated titanium oxide in said gel or sol, and the resulting aqueous titanic acid solution is heated in the presence of at least one compound selected from inorganic compounds of metals belonging the Group II, III, IV, V, VI and VIII of the periodic table.

Abstract: A radiolabeled protein composition adapted for radiation therapy which comprises a radioisotope and a protein material containing about 6 or more percent amino acids which have a sulfhydryl-containing side chain. A method for carrying out radiation synovectomy of arthritic joints. Rhenium radiolabeled protein microspheres are administered which contain cysteine and other amino acids. A method for radiolabeling a protein composition whereby the composition is treated with a reducing agent capable of reducing disulfides to sulfhydryls prior to radiolabeling.

Abstract: Biomodulators, optionally linked to imaging-active moieties, can be administered to a host to enhance images thereof, e.g., NMR-, X-ray- or radio-images, preferably by increasing aberrant tissue signal intensity. Biomodulators can also condition tissue to enhance uptake of otherwise non-specific imaging agents. When linked to drugs, biomodulators can target the same to particular sites in the body.

Abstract: A novel liquid crystal compound having an intermediate group of a cis-1,4-substituted 2-butenyl group, low viscosity and a broad mesomorphic temperature range is provided, which compound is expressed by the following formula: ##STR1## wherein R.sup.1 represents an alkyl group of 1 to 10 carbon atoms, n represents 1 or 2, X represents a hydrogen atom, an alkyl group, a halogen atom, a cyano group, an alkoxy group, a methyl group substituted by 1 to 3 halogen atom(s) or a trihaloalkoxy group, and Y and Y' each independently represents a hydrogen atom, or a halogen atom.

Abstract: This invention relates to an improved process and apparatus for preparing a product predominant in decabromodiphenylethane, the process comprising heat treating the product in a product treating and storage system for a period of time and at a temperature which are sufficient to reduce the amount of unreacted bromine in the product wherein the product treating and storage system comprises an insulated storage vessel, and a heated stream of carrier gas for carrying and suspending the product particles in the storage vessel during the heat treatment step.

Abstract: A process for increasing the bleaching efficiency of an inorganic persalt or hydrogen peroxide by adding to said persalt or H.sub.2 O.sub.2 an activating agent. The activating agent is an acetylated gluconic acid derivative, such as N-methyl-N-acetyl pentaacetyl gluconamide, N-methyl-N-acetyl pentaacetyl gluconamide or tetraacetyl gluconolactone. The invention also relates to the acetylated gluconic acid derivatives themselves.

Abstract: The present invention relates to dispersing agents or their salts, comprisingA the reaction product of one or more polyisocyanates having an average functionality of from 2.0 to 5, withB a mixture from B.sub.1 monohydroxyl compounds and B.sub.2 monohydroxy-, monocarboxylic acid compounds, or monoamino-, monocarboxylic acid compounds andC a compound containing at least one basic ring nitrogen and an isocyanate-reactive group, in which of the isocyanate groups about 30-70% are reacted with B and about 30-70% with C,and the preparation of such dispersing agents.

Abstract: Process for the preparation of nitride complexes of transition metals for use as radiopharmaceutical products or for the synthesis of novel pharmaceutical products. The process consists in reacting an oxygenic transition metal compound such as 99m.sub.Tc, 186.sub.Re or 188.sub.Re, with a first nitrogenous ligand such as sodium nitride or a nitrogenous compound such as S-methyl, N-methyl dithiocarbazate, and a reducing agent consisting of either tin (II) or a dithionite. The product so obtained can be used for the preparation of radiopharmaceutical products by a reaction with a second ligand such as sodium dithiocarbamate.